1. Home
  2. SKYH vs BBIO Comparison

SKYH vs BBIO Comparison

Compare SKYH & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sky Harbour Group Corporation

SKYH

Sky Harbour Group Corporation

HOLD

Current Price

$10.04

Market Cap

418.4M

Sector

Industrials

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$66.97

Market Cap

15.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYH
BBIO
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
418.4M
15.9B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
SKYH
BBIO
Price
$10.04
$66.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
25
Target Price
$13.13
$86.33
AVG Volume (30 Days)
123.7K
1.8M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
105.11
N/A
EPS
N/A
N/A
Revenue
$27,540,000.00
$502,076,000.00
Revenue This Year
$78.89
$89.45
Revenue Next Year
$73.15
$73.78
P/E Ratio
N/A
N/A
Revenue Growth
86.57
126.26
52 Week Low
$8.22
$48.78
52 Week High
$11.70
$93.42

Technical Indicators

Market Signals
Indicator
SKYH
BBIO
Relative Strength Index (RSI) 40.90 20.08
Support Level $9.07 $62.94
Resistance Level $10.24 $70.49
Average True Range (ATR) 0.23 2.44
MACD -0.04 -0.92
Stochastic Oscillator 21.00 2.92

Price Performance

Historical Comparison
SKYH
BBIO

About SKYH Sky Harbour Group Corporation

Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: